Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 1999

View Archived Issues

Parathyroid hormone prolongs the survival of osteoblasts

Additional U.S. patents will issue for Cortex's Ampakines

SangStat's cold storage solution for donor hearts cleared by FDA

Cubist expands collaboration with Merck & Co.

Ribozyme acquires ribozyme assets from Innovir

FDA approves Cleocin vaginal ovules for treatment of bacterial vaginosis

Ciba Vision and QLT PhotoTherapeutics seek approval for Visudyne in U.S., Switzerland

Titan makes significant progress during Q2 1999

Cangene cancels current offer to acquire Hyal

New company to focus on treatments for Alzheimer's disease

Remicade receives E.U. approval for Crohn's disease treatment

Tularik describes agents for lipoprotein disorders acting via a novel mechanism

Neuronal calcium channel blockers in the pipeline at Toyama

Shionogi synthesizes potent 5-HT7 receptor ligands for CNS, CV disorders

Fuji Pharmaceutical describes therapeutic activity of dual MMP/TACE inhibitors

Merck invention centers on GABA-A receptor ligands for epilepsy, anxiety

Novel uricosuric agents claimed by Yamasa Shoyu

Sucrose-formulated rFVIII: a safe and effective second-generation factor VIII developed by Bayer

In vitro interactions of novel platelet substitute Synthocytes with platelets

Fibrinogen antagonist gantofiban is a promising treatment for peripheral arterial occlusion

FDA approves Organon's short-acting neuromuscular blocker Raplon

P2T antagonist shows antithrombotic effects in blood from patients with unstable angina

Aronex expands Atragen phase II clinical trial in prostate cancer

Axonyx: Q2 1999 highlights

SanOrg-34006, a promising new antithrombotic, is safe for use in the elderly

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...